Home » Stocks » BPMC

Blueprint Medicines Corporation (BPMC)

Stock Price: $82.41 USD -0.38 (-0.46%)
Updated Jun 21, 2021 1:06 PM EDT - Market open
Market Cap 4.83B
Revenue (ttm) 809.14M
Net Income (ttm) 325.12M
Shares Out 58.02M
EPS (ttm) 5.66
PE Ratio 14.57
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 21
Last Price $82.41
Previous Close $82.79
Change ($) -0.38
Change (%) -0.46%
Day's Open 82.59
Day's Range 81.91 - 83.80
Day's Volume 829,457
52-Week Range 66.20 - 125.61

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The FDA approves Blueprint Medicines' (BPMC) lead drug, Ayvakit, for treating adult patients with advanced systemic mastocytosis.

4 days ago - Zacks Investment Research

CAMBRIDGE, Mass., June 16, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for th...

4 days ago - PRNewsWire

CAMBRIDGE, Mass., June 4, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on June 1, 2021, the Compensation Committee of Blueprint Medicines' Board of...

2 weeks ago - PRNewsWire

CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.

3 weeks ago - PRNewsWire

CAMBRIDGE, Mass., May 19, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the presentation of updated Phase 1/2 ARROW trial data demonstrating durable clinical benefi...

1 month ago - PRNewsWire

Biotech stocks frequently make big moves on a single trial result or FDA ruling. These 8 drugmakers are worth watching amid important events on deck this summer.

Other stocks mentioned: ALKS, BIIB, BMY, MYOV, PRVB, SNY, VRTX
1 month ago - Kiplinger

CAMBRIDGE, Mass., May 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Percy Carter, MBA, Ph.D.

1 month ago - PRNewsWire

CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on May 1, 2021, the Compensation Committee of Blueprint Medicines' Board of D...

1 month ago - PRNewsWire

Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.

1 month ago - Zacks Investment Research

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past year to ($1.72), which beat the e...

1 month ago - Benzinga

CAMBRIDGE, Mass., April 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2021.

1 month ago - PRNewsWire

CAMBRIDGE, Mass., April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.

1 month ago - PRNewsWire

If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.

Other stocks mentioned: BDSI, FLGT
2 months ago - GuruFocus

Blueprint Medicines is setting itself up to become the leader in precision oncology.

2 months ago - The Motley Fool

CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) progra...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precisio...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:00 a.m.

2 months ago - PRNewsWire

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the co...

3 months ago - PRNewsWire

CAMBRIDGE, Mass., March 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy...

3 months ago - PRNewsWire

The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.

3 months ago - Zacks Investment Research

Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.

4 months ago - Zacks Investment Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.55% and -1.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate ...

4 months ago - Benzinga

CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended D...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,...

4 months ago - PRNewsWire

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

Other stocks mentioned: HALO, NVAX
5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company's research and development organization. Effective a...

5 months ago - PRNewsWire

We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.

Other stocks mentioned: HALO, MRNA
5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,...

5 months ago - PRNewsWire

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's second drug, Gavreto, gets approved for two types of cancer indications.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Dec. 4, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,...

6 months ago - PRNewsWire

The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.

6 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,...

6 months ago - PRNewsWire

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

Other stocks mentioned: ADPT, BLUE, NVAX, RHHBY
7 months ago - The Motley Fool

Keeping this in mind, let's analyze whether Blueprint Medicines Corporation (NASDAQ:BPMC) is a good investment right now by following the lead of some of the best investors in the world and piggybacking...

7 months ago - Insider Monkey

CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,...

7 months ago - PRNewsWire

Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Blueprint Medicines' (BPMC) both bottom and the top line trump estimates in Q3. Ayvakit's sales rise sequentially.

7 months ago - Zacks Investment Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 71.96% and 31.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in ...

Other stocks mentioned: ANAB, DRNA, QURE, SPRO
7 months ago - Insider Monkey

Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.

8 months ago - Zacks Investment Research

Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma

8 months ago - Seeking Alpha

Blueprint Medicines' (BPMC) Ayvakyt gains a conditional marketing approval from the European Commission for unresectable/metastatic gastrointestinal stromal tumors harboring the PDGFRA D842V mutation.

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Sept. 25, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherap...

8 months ago - PRNewsWire

Blueprint Medicines (BPMC) reports positive top-line results from the EXPLORER and the PATHFINDER studies, which are evaluating Ayvakit for patients with advanced systemic mastocytosis. Shares up.

8 months ago - Zacks Investment Research

Blueprint Medicines on Tuesday reported positive test results for its treatment for a potentially fatal rare disease, sending BPMC stock to an eight-month high extending beyond a buy zone. The post Blue...

8 months ago - Investors Business Daily

CAMBRIDGE, Mass., Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherap...

9 months ago - PRNewsWire

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available... [Read more...]

Industry
Biotechnology
IPO Date
Apr 30, 2015
CEO
Jeffrey Albers
Employees
451
Stock Exchange
NASDAQ
Ticker Symbol
BPMC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 14 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is 119.69, which is an increase of 45.24% from the latest price.

Price Target
$119.69
(45.24% upside)
Analyst Consensus: Buy